NHWK News and Press, NightHawk Biosciences Inc. From 01/03/24

DURHAM, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced its Scorpius BioManufacturing subsidiary (&...

Next phase of multi-million-dollar project to include scaling up cGMP manufacturing for phase 1 trial targeting infectious disease CDMO services attracting considerable interest as state-of-the-art San Antonio facility helps address industry-wide scarcity for large molecule manufacturin...

2023-12-19 17:00:42 ET More on NightHawk Biosciences NightHawk divesting Elusys assets to focus on CDMO contracts Seeking Alpha’s Quant Rating on NightHawk Biosciences Historical earnings data for NightHawk Biosciences Financial information for NightHa...

Manufacturing run at Scorpius’ state-of-the-art San Antonio microbial facility sets the stage for commercial manufacturing Advances multi-million dollar biomanufacturing contract awarded earlier this year; set to expand upon client’s regulatory filing and start o...

2023-12-12 10:49:02 ET More on NightHawk Biosciences Seeking Alpha’s Quant Rating on NightHawk Biosciences Historical earnings data for NightHawk Biosciences Financial information for NightHawk Biosciences For further details see: NightHawk divesti...

Over $20 million in signed manufacturing contracts which include premier biotech/pharma companies and research institutes Elusys divestiture and R&D cuts expected to eliminate over $40 million in commitments and reduce operating expenses by more than $13 million per ye...

2023-11-20 16:52:50 ET More on NightHawk Biosciences Seeking Alpha’s Quant Rating on NightHawk Biosciences Historical earnings data for NightHawk Biosciences Financial information for NightHawk Biosciences For further details see: NightHawk Bioscie...

DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) , a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative therapies, today provided strategic, financial, and...

2023-08-14 17:01:43 ET NightHawk Biosciences press release ( NYSE: NHWK ): Q2 GAAP EPS of -$0.53 misses by $0.08 . Revenue of $0.7M (+1300.0% Y/Y) misses by $0.2M . As of June 30, 2023, the Company had approximately $18.6 million in cash, cash equivalents, and ...

DURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) , a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative medical countermeasures that combat unmet and emerg...